Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (mainland).
Department of General Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China (mainland).
Med Sci Monit. 2019 Feb 7;25:1053-1060. doi: 10.12659/MSM.912843.
BACKGROUND This study aimed to investigate the effectiveness of perioperative parecoxib sodium combined with transversus abdominis plane (TAP) block on postoperative pain management following hepatectomy in patients with hepatocellular carcinoma (HCC). MATERIAL AND METHODS One hundred patients with HCC who underwent hepatectomy were randomized into a study group (n=51) and a control group (n=49). The study group received 40 mg of parecoxib sodium 30 minutes before anesthetic induction, and 150 mg of 0.375% ropivacaine with 5 mg dexamethasone as TAP inhibitors, before closing the abdominal incision. The control group received 40 mg of placebo 30 minutes before anesthetic induction, without TAP block. Postoperatively, all patients received patient-controlled intravenous analgesia (PCIA) and evaluation with subjective visual analog scale (VAS) pain scores. Data on adverse events, postoperative ambulation (>6 hours/day), time of flatus and defecation, and hospitalization duration were recorded. RESULTS Pain scores of the study group were significantly lower compared with the control group on the first three postoperative days. No significant differences were found between the two groups in terms of adverse events. In the study group, the number of cases of postoperative ambulation was significantly more than the control group. The onset of flatus and defecation and duration of hospital stay in the study group were significantly shorter in the study group compared with the control group. CONCLUSIONS Parecoxib sodium combined with TAP block effectively reduced postoperative pain, improved ambulation, improved gastrointestinal function, and shortened hospitalization time following hepatectomy in patients with HCC without adverse effects.
本研究旨在探讨围手术期帕瑞昔布钠联合腹横肌平面(TAP)阻滞对肝细胞癌(HCC)患者肝切除术后疼痛管理的效果。
100 例 HCC 患者行肝切除术,随机分为研究组(n=51)和对照组(n=49)。研究组麻醉诱导前 30 分钟给予 40mg 帕瑞昔布钠,在关闭腹部切口前给予 150mg 0.375%罗哌卡因加 5mg 地塞米松作为 TAP 抑制剂。对照组麻醉诱导前 30 分钟给予 40mg 安慰剂,不进行 TAP 阻滞。术后所有患者均接受患者自控静脉镇痛(PCIA),并采用主观视觉模拟评分(VAS)评估疼痛。记录不良反应、术后活动(>6 小时/天)、排气排便时间和住院时间。
研究组术后第 1、2、3 天的疼痛评分明显低于对照组。两组不良反应发生率无显著差异。研究组术后活动例数明显多于对照组。研究组术后排气排便时间和住院时间明显短于对照组。
帕瑞昔布钠联合 TAP 阻滞可有效减轻 HCC 患者肝切除术后疼痛,促进术后活动,改善胃肠功能,缩短住院时间,且无不良反应。